Keysight Technologies and KT SAT complete successful handover from a live GEO connection to an emulated LEO link, creating a dependable way to study real NTN behaviour before constellations deployed.

Mobile carrier KT is facing mounting scrutiny after a government investigation found the company concealed a major malware infection last year. According to a joint government-private investigation ...

Kymera Therapeutics (NASDAQ:KYMR) presented its third quarter 2025 results on November 4, highlighting its progress in developing novel protein degradation therapies while facing financial challenges.

WATERTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

The STAT6 degrader KT-621 represents Kymera’s most advanced program, with the company highlighting its potential across multiple inflammatory conditions. Kymera emphasized the target’s strong genetic ...

Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT ...

South Korea-based KT opened an innovation hub aimed at driving AI transformation (AX) among local businesses in partnership with Microsoft, building on an existing strategic alliance. The ...

KT Corporation remains a buy with multiple positives. It is gaining market share in the Korean wireless industry at the expense of a key rival, judging by its favorable 2Q25 operating metrics. The ...

The Browns are second in waiver priority, but they decided not to wait to see if they could grab guard KT Leveston off waivers. Instead, the Browns have traded a 2028 seventh-round draft pick to the ...

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation ...